ADAMTS13与炎症反应在冠状动脉粥样硬化性心脏病中的研究进展

Advances of ADAMTS13 and inflammatory responses in coronary atherosclerotic heart disease

血管性血友病因子裂解蛋白酶(ADAMTS13)作为体内活酶可特异性灭活血管性血友病因子(vWF),降低其黏附活性,进而减少血小板在血管受损处的黏附,其含量与活性的改变与炎症反应及动脉粥样斑块的形成密切相关。近年来关于冠心病的炎症反应机制已被众多实验证实,越来越多的研究证明ADAMTS13在冠心病的发生、发展和预后中起重要作用。本文对近年来关于炎症反应、冠状动脉粥样硬化与ADAMTS13关系研究进展作一总结。

As an enzyme in vivo,ADAMTS13 specifically inactivated von Willebrand factor(vWF),downregulate adhesion activityof VWF,then reduce the adhesion of platelets to vascular damage,its content and activation change is closely related to the inflammatory response and the formation of coronary atherosclerotic plaque.The inflammatory response mechanism of coronary heart disease has been confirmed by many experiments in recent years,more and more research has proved that ADAMTS13 plays an important role in the occurrence,development and prognosis of coronary heart disease.This article is to summarize the research progress on the relationship between inflammatory response,coronary atherosclerosis and ADAMTS13 in recent years.